Board of Directors
Dr. Barrett is a General Partner at New Enterprise Associates (NEA). He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices, healthcare information systems, and healthcare services companies. He is a director of Cardioxyl Pharmaceuticals, GlycoMimetics, Inhibitex, Nucleonics, Peptimmune, Predictive Biosciences, Proteostasis Therapeutics, Ruxton Pharmaceuticals, Sensors for Medicine and Science, Supernus Pharmaceuticals, Targacept, and Zosano Pharma. Prior to joining NEA, Dr. Barrett served as Founder, Chairman, and CEO of Sensors for Medicine and Science, where he remains Chairman. Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, President and CEO of Life Technologies, and President and CEO of Bethesda Research Labs. Previously, he worked in various divisions of GlaxoSmithKline. Dr. Barrett received a Ph.D. in Biochemistry at the University of Tennessee, an M.B.A. from the University of Santa Clara, and a B.S. in Chemistry from Boston College.
Omid Farokhzad is an Associate Professor at Harvard Medical School (HMS) and a physician-scientist in the Department of Anesthesiology at Brigham and Women’s Hospital (BWH). Dr. Farokhzad directs the Laboratory of Nanomedicine and Biomaterials at BWH. He is a faculty member of the Brigham Research Institute Cancer Research Center at BWH. He is additionally a member of the Dana Farber/Harvard Cancer Center Programs in Prostate Cancer and Cancer Cell Biology. He is a Research Affiliate in the MIT Institute for Medical Engineering and Science. Dr. Farokhzad has extensive experience with the development of therapeutic nanoparticle technologies; most notably, he pioneered the high throughput development and screening of multifunctional nanoparticles for medical applications. Dr. Farokhzad has authored more than 85 papers and is an inventor of more than 70 issued/pending patents. The nanoparticle technologies that Dr. Farokhzad has developed formed the foundation for the launch of three venture-backed biotechnology companies, BIND Therapeutics, Selecta Biosciences and Blend Therapeutics. These companies are translating the aforementioned academic innovations towards clinical development. He serves as Director on the boards of BIND and Blend, and as Director and Vice Chairman on the board of Selecta. Dr. Farokhzad was elected to the College of the Fellows of the American Institute of Medical and biological Engineering. He completed his post-graduate clinical and post-doctoral research trainings, respectively, at the BWH/HMS and MIT in the laboratory of Dr. Robert Langer. He received his M.D. and M.A. from Boston University School of Medicine.
Mr. Hutt is a Senior Counsel in the Washington, D.C. law firm of Covington & Burling specializing in food and drug law. Mr. Hutt served as Chief Counsel for the Food and Drug Administration during 1971-1975. He is the co-author of the casebook used to teach food and drug law throughout the country. Since 1994, he has taught a full course on food and drug law each winter term at Harvard Law School. Mr. Hutt has been a member of the Institute of Medicine of the National Academies since it was founded in 1971. He currently serves on the Working Group on Innovation in Drug Development and Evaluation for President Obama’s Council of Advisors on Science and Technology, and he recently served on the Panel on the Administrative Restructuring of the National Institutes of Health. He also serves on academic and venture capital advisory boards and on the boards of numerous startup biotechnology companies. He was named by Washingtonian magazine as one of Washington’s 50 best lawyers (out of more than 40,000) and as one of Washington’s 100 most influential people; by the National Law Journal as one of the 40 best health care lawyers in the United States; and by European Counsel as the best FDA regulatory specialist in Washington, D.C.
Mr. Iwicki has more than 23 years of experience as a pharmaceutical industry leader managing all stages of drug development in multiple therapeutic areas. He has extensive experience managing high-performance teams and has been instrumental in the success of a number of drugs, including Prilosec®, Diovan®, Zelnorm®, Lunesta®, and Latuda®. Prior to joining Blend, Mr. Iwicki was CEO of Sunovion Pharmaceuticals, where he provided leadership to the successful launch of Sunovion, which was created after the $2.6 billion acquisition of Sepracor by Dainippon Sumitomo Pharmaceuticals. At Sepracor, Mr. Iwicki served as Chief Commercial Officer for the company’s six marketed products with over $1.2 billion in annual sales. Prior to joining Sepracor in 2007, he was the Senior Vice President and head of the $4 billion cardiovascular business unit at Novartis Pharmaceuticals, and before that held management positions at Astra Merck and Merck.
Mr. Kania is Managing Partner and Chairman of Flagship Ventures, a firm he co-founded in 2000. Mr. Kania has 29 years of experience in the venture capital industry and has been involved in the founding, financing, and development of dozens of life science technology companies including several that have emerged as major independent enterprises or significant acquisitions. Mr. Kania currently serves as a director of several other privately held companies. Mr. Kania earned his undergraduate degree in physics from Dartmouth College and his MBA from Harvard Business School. While at Dartmouth, he was an All-American Track and Field athlete and a national and collegiate record holder.
Dr. Langer is renowned for his pioneering contributions in the use of biomaterials in drug delivery and tissue engineering. He is the author of more than 1,175 scientific papers and a named inventor on more than 800 issued or pending patents worldwide; his patents have been licensed or sublicensed to more than 220 pharmaceutical, chemical, biotechnology, and medical device companies. Dr. Langer is the recipient of more than 210 major awards, including the National Medal of Science, the highest civilian honor bestowed by the United States; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize in the field of engineering; the Millennium Prize, the world’s largest technology prize; the Priestley Medal, the highest award conferred by the American Chemical Society; and the Lemelson-MIT prize, the world’s largest prize for invention. He is the most cited engineer in history and is one of few individuals to have been elected to all three U.S. national academies—the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. He is the co-founder of more than 20 companies, including BIND Biosciences, Selecta Biosciences, Momenta, and Transform. Dr. Langer holds a B.S. from Cornell University and an Sc.D. from MIT, both in Chemical Engineering.
Aymeric Sallin is the Founder and CEO of NanoDimension, a nanotechnology-focused venture capital firm, with offices in Zurich, Switzerland and Menlo Park, California. Mr. Sallin is currently on the Board of Directors of Crocus Technology SA and Selecta Biosciences as well as the Advisory Board of the Physics Department of the Federal Institute of Technology (EPFL) in Lausanne, Switzerland. Since 2001, he has actively promoted and stimulated nanotechnology around the world, receiving the "NSTI Fellow Award" for outstanding contributions to the advancement of the international nanotechnology community. In 2010, he was voted “Top 20 Under 40” in Switzerland by Bilan magazine and as one of Switzerland’s 300 most influential people in 2011. Mr. Sallin holds a Masters in Physical Engineering from EPFL.